As a potent vasodilatory Gαi2-coupled receptor, targeting RXFP1 may represent a promising avenue to study Gi-coupled receptor based drugs in cardiovascular disease that may allow clarifying specific roles for Gαi2 and Gαi3 in response to GPCR activation directly in the vasculature. Here, RXFP1 is linked to cardiovascular disorder.